Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.

Drugs - 1 Apr 2018

Heo Young-A, Deeks Emma D

Abstract excerpt

A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir; Vosevi®) is approved in the EU for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in adults. In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Drug Approval
Share to Heterocyclic Compounds, 4 or More Rings

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Quinoxalines

Share to Sofosbuvir

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 29546556
DOI: 10.1007/s40265-018-0895-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.PMID 29546556Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.Semantic proximity Read ↗

Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.Semantic proximity Read ↗

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.Semantic proximity Read ↗

Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.Semantic proximity Read ↗

A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.Semantic proximity Read ↗

Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.Semantic proximity Read ↗

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.